ORI-INDUSTRIES
4.10.2021 07:02:05 CEST | Business Wire | Press release
London based edge computing pioneer Ori Industries is partnering with VMware, Inc. (NYSE: VMW), a leading innovator in enterprise software, to facilitate enterprise implementation of edge computing across hybrid, telco and multi-cloud deployments. The interoperability of VMware Telco Cloud Platform and Ori Global Edge reduces complexity, increases service velocity, and manageability of cloud-native service delivery at the edge.
According to Gartner 1 , “edge computing is entering the mainstream”; however, many enterprises struggle with their existing cloud deployments proving to be a barrier to edge adoption. Ori and VMware’s partnership will help overcome this challenge by offering a fully functioning edge platform that connects to any cloud environment from telco to hybrid to multi-cloud.
Ori Global Edge on VMware Telco Cloud Platform is a managed cloud service offering that delivers a multi-connected edge by using multiple points of presence (PoP) that connect to the telco and communications service provider (CSP) infrastructure on one end and different clouds on the other end. The solution2 enables CSPs to offer multi-access edge computing (MEC) capabilities, which allow them to greater monetize their 5G offering to the enterprise. At the same time, it allows them to reduce their backhaul costs through intelligent workload placement.
Customers will benefit from service availability at the edge with low latency, highly-available applications generating and processing data locally without overhead for data transfer back to the cloud for processing. Extracting, analysing and using data at the edge permits a new class of enterprise services for enhanced customer experience.
Stephen Spellicy , vice president of product marketing, Service Provider and Edge, VMware, said, “Enterprises are looking for new ways to engage customers and deliver next-generation experiences. That means having the right application deployed where the user is. Edge computing is the final piece of the puzzle and working with Ori Industries’ multi-access edge computing platform will give mutual customers the ability to deploy a solution that helps cover all their environments – whether telco, hybrid, multi-cloud or edge – to meet their business needs.”
Douglas Mancini , CCO at Ori Industries said “Edge computing offers enterprises immense opportunities to not only deliver new innovative solutions but also reinvent their existing infrastructure in a more efficient way: Enterprises have learned that a pure cloud-first model has failed to deliver the expected value or agility, and Ori Global Edge is helping do just that. By combining our edge computing expertise with VMware Telco Cloud Platform and multi-cloud leadership, we are able to offer enterprises a way of harnessing the power of edge and reaping the benefits of being able to use data near to its creation.”3
For more information visit: https://ori.co/ .
About Ori Industries
Ori Industries is laying the foundation for the global rollout of edge computing services. The company’s edge platform simplifies workload provisioning across public, Telco, hybrid, and multi-cloud infrastructure to support countless new and emerging enterprise use cases. Ori Industries is based in London with a global workforce. For more information, please visit https://www.ori.co/ .
VMware and VMware Telco Cloud Platform are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
1
https://www.gartner.com/en/documents/3992656/2021-strategic-roadmap-for-edge-computing
2
Solution Overview: https://www.vmware.com/content/dam/digitalmarketing/vmware/en/pdf/microsites/telco/vmware-ori-solution-brief.pdf
3
Video Interview: https://www.youtube.com/watch?v=R-fUFNElWzo
View source version on businesswire.com: https://www.businesswire.com/news/home/20211003005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom